At a glance
ClinicalIndex Comparison RecordN/ACompleted· 60 enrolled
Drug / intervention
3R 3'R Zeaxanthin +2 moredrug
Likely dose
3R 3'R Zeaxanthin 8 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Randomized, Double Blind, Lutein Controlled Study of Zeaxanthin and Visual Function in Atrophic Age Related Macular Degeneration Patients
In Brief
A clinical study evaluating 3R 3'R Zeaxanthin, Lutein, and 1 other intervention for Age Related Macular Degeneration and Cognition Disorders. Completed, enrolled 60 participants across 1 site.
Detailed Summary
To evaluate if supplementation of zeaxanthin (with or without Lutein) is beneficial to patients with early and moderate Atrophic Age Related Macular Degeneration.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
CollaboratorsKowa Company, Ltd., IMAGE TECHNOLOGIES INC.
Timeline
N/ACompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartNov 2007
First PostedNov 2007
Primary CompletionMay 2009
Study CompletionJun 2009
TodayJul 2026
First PostedNov 29, 2007
Enrollment StartNov 1, 2007
Primary CompletionMay 1, 2009
Study CompletionJun 1, 2009
TodayJul 2, 2026
Enrollment to primary: 1.5 yearsPosted 18.6 years ago
Interventions
3R 3'R Zeaxanthindrug
8 mg per day during 12 months
Luteindietary
9 mg of Lutein during 12 months
Lutein and Zeaxanthindietary
8 mg of lutein and 8 mg of Zeaxanthin administered during 12 months